4 06, 2020

Antiepileptic Drugs and Bone Health: Current Concepts

By |2020-06-04T10:53:56-07:00June 4th, 2020|Brief Bulletins from the Field, We Know Psychiatry|3 Comments

Chronic use of antiepileptic drugs (AEDs) can induce the development of adverse effects on bone metabolism. In epileptic patients treated with AED, the monitor- ing of biochemical markers of bone turnover, such as the measurement of serum 25 (OH) vitamin D, bone mineral density, before the beginning of the treatment [...]

4 06, 2020

Demographic Variation in the Use of Prazosin for Treatment of Sleep Disturbance in Combat Veterans with PTSD

By |2020-06-04T10:47:07-07:00June 4th, 2020|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

ABSTRACT ~ Objective: Off-label use of prazosin for posttraumatic stress disorder-related sleep disturbances (PTSD-SD) is widespread in Veterans Health Administration (VA) settings, but clinical trials have had mixed results. Trial criteria may exclude significant sub-groups, and therefore a 2018 study may not provide the final evidence of prazo- sin efficacy [...]

4 06, 2020

Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder at Any Phase of Illness and at least Mild Symptom Severity

By |2020-06-04T10:50:45-07:00June 4th, 2020|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

ABSTRACT ~ Objectives: To sequentially study the effectiveness of lithium and divalproex monotherapy and adjunctive therapy with quetiapine or lamotrigine in the acute and continuation treatment of bipolar I or II disorder at any phase of illness and at least mild symptom severity. Methods: From June 2011 to December 2016, [...]

4 06, 2020

Cannabis Use and its Association with Psychological Disorders

By |2020-10-02T11:42:42-07:00June 4th, 2020|Brief Bulletins from the Field, Featured|0 Comments

ABSTRACT ~ Purpose of Review: This is a comprehensive review of the association between cannabis use and psychological disorders. It reviews the latest and seminal evidence that is available and attempts to conclude the strength of such association. Recent Findings: Cannabis is a flowering plant with psychoactive properties, attributed to [...]

6 02, 2020

Depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram

By |2020-10-02T11:43:24-07:00February 6th, 2020|Brief Bulletins from the Field, Featured|0 Comments

In a recent study, researchers described treatment-emergent sexual dysfunction (TESD) and tolerability following a switch from selective serotonin reuptake inhibitor (SSRI: citalopram, paroxetine, or sertraline) monotherapy to vortioxetine or escitalopram monotherapy in adults with well-treated major depressive disorder (MDD) and SSRI-induced sexual dysfunction. The study was published in CNS Spectrums. [...]

24 10, 2019

Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity

By |2019-10-24T09:38:15-07:00October 24th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Although currently available antidepressants increase monoamine levels soon after the start of treatment, therapeutic benefits are often delayed by several weeks and the majority of patients with major depressive disorder fail to achieve an adequate response to first- or second-line therapies targeting monoamines. The recent approval of the NMDA (N-methyl-d-aspartate) [...]

24 10, 2019

Over-the-Counter Device Offers Long-Lasting Pain Relief, New Data Shows

By |2019-10-24T09:28:34-07:00October 24th, 2019|Brief Bulletins from the Field, We Know Psychiatry|1 Comment

A novel, noninvasive, over-the-counter electromagnetic neuromodulation device (ActiPatch, BioElectronics Corp.) appears to deliver long-lasting relief in chronic pain patients. Results of a long-term prospective study that included 240 patients who had previously experienced chronic pain relief with the device showed that at 6 months, 97% of the 240 participants sustained [...]

29 07, 2019

Benefit Seen in the Use of Intranasal Insulin in Slowing Dementia

By |2019-07-29T16:49:18-07:00July 29th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Daily intranasal insulin may be effective in slowing progression of mild cognitive impairment (MCI) or Alzheimer's disease (AD), new research suggests. The findings were presented at the Alzheimer's Association International Conference (AAIC) 2019. Investigators found intranasal insulin administered via a novel delivery device slowed the rate of cognitive decline by [...]

27 07, 2019

Is Methamphetamine-Induced Psychosis Reversible

By |2020-11-29T08:46:29-08:00July 27th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

According to evidence-based reviews, the answer is a qualified “Maybe.” Chronic methamphetamine use can induce pathological brain changes in the brain. Users can develop thought, mood, and behavioral disorders, including psychosis. Such effects may persist even after extended abstinence. Because cognitive deficits can affect how well patients respond to treatment, interventions [...]

28 03, 2019

Study Shows the Need for Psychiatric Care to be Integrated into Cancer Treatment

By |2019-03-28T14:15:40-07:00March 28th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Patients with prostate, bladder or kidney cancers are at greater risk of dying if they have had psychiatric care prior to the cancer treatment. In addition, patients with these cancers show greater suicide risk than the general population, even once the data is corrected for previous psychiatric care. These are [...]

Go to Top